Tarsus Pharmaceuticals Q3 2026: What's Behind the Giant EPS Miss
As seen on the 24/7 Wall St. homepage on November 3, 2026.
The loss per share is an accounting artifact: $632.2 million of acquired in-process R&D from the iRenix and Alkeus deals ran straight through the income statement. Underneath it, XDEMVY sales grew about 64% year over year, exceeding expectations on revenue. Management points to five medicines in five years, with no formal guidance.
Continue ReadingShow less
Tarsus Pharmaceuticals reported Q3 2026 revenue of $194.57 million, beating expectations against the $191.66 million consensus. That topline beat was powered entirely by XDEMVY, the company's sole marketed product and the only FDA-approved treatment for Demodex blepharitis. Net product sales for XDEMVY grew roughly 64% year over year, driven by higher prescription volume and improvements in gross-to-net discounts.
The GAAP loss per share of $14.40 came in well below the $1.77 consensus estimate, missing expectations, and the number is almost entirely an accounting artifact. Tarsus completed two acquisitions during the quarter, iRenix Medical and Alkeus Pharmaceuticals, and expensed $632.2 million of acquired in-process research and development straight through the income statement. Under accounting rules, that charge is required when acquired assets have no alternative future use. An additional $23.5 million in Alkeus transaction and integration costs also ran through SG&A in the period.
Strip out the acquisition charges and the underlying business looks considerably different. The company's gross margin held at approximately 93%, and the average number of eye care professionals prescribing XDEMVY at least daily rose about 20% during the quarter. Refills made up roughly 20% of XDEMVY prescriptions, a sign of growing patient retention. CEO Bobby Azamian noted that XDEMVY has dispensed more than one million bottles and generated $1 billion in cumulative net product sales since its launch three years ago.
Sponsored
The two acquisitions substantially expand Tarsus's pipeline, and the company now points to five potential medicines over the next five years. Near-term clinical catalysts include topline data from the Phase 2 Kore trial of TP-04 in ocular rosacea and the Phase 2 Calliope trial of TP-05 for Lyme disease prevention, both expected in the first half of 2027. The Phase 3 Northstar trial of gildeuretinol for Stargardt disease, a condition with no FDA-approved treatment, is targeting topline results in 2029.
Tarsus did not provide formal financial guidance for the coming quarters. Cash and equivalents stood at $136.53 million, up 21% year over year, while total liabilities more than doubled and shareholders' equity declined roughly 69%, both shifts reflecting the costs and financing structure of the acquisitions. Investors will need to weigh the company's concentrated revenue base in a single product against a pipeline that now carries readouts extending several years out.
Mentioned: TARS